Phase 2 N=192 Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
COVID-19
Primary: Incidence of SARS-CoV-2 Clearance — 34.2; 38.5; 30.3; 27.0 percentage of paticaipants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=106 Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
Metastatic Cancer
Primary: Objective Response Rate — 11; 6 Participants
Phase 2 N=327 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Alzheimer Disease
Primary: Change From Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population) — -8.39; -13.27; -10.07 score on…
Phase 2 N=1,015 Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
Pneumococcal Vaccines
Primary: Percentage of Subjects Reporting Solicited Local Reactions Within 7 Days After Vaccination (Redness, Swelling, and Pain at Injection Site) in Each Age Group — 66.8…
Phase 2 N=174 Mindfulness-based Cognitive Coping for ADRD Caregivers
Caregiver Stress
Primary: Center for Epidemiological Studies Depression Scale — 17.1; 21.98 score on a scale
Phase 2 N=77 Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
Nonproliferative Diabetic Retinopathy
Primary: Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36 — 5.0; 0; 4.8 percentage of subjects
Phase 2 N=16 IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Head and Neck Carcinoma
Primary: Participants Experiencing Adverse Events — 10 Participants
Phase 2 N=103 Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
Chronic Hepatitis B
Primary: Percentage of Participants Who Achieved Functional Cure — 2.4; 2.5; 0.0 percentage of participants
Phase 2 N=35 Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: Rate of Confirmed MRD-negative Response — 0 proportion of patients
Phase 2 N=111 Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: Best Response Rate by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Upon Central Radiologic Assessment — 0; 0; 23; 9 Participants
Phase 2 N=420 A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
Essential Tremor
Primary: Change From Baseline to Week 12 on the TETRAS Composite Outcome Score as Summarized by Each Dose of JZP385 and Placebo — -6.3; -5.8; -6.7; -7.5 score on a scale
Phase 2 N=1,256 A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
Influenza, Human
Primary: Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) — 0; 2; 2; 2 Participants
Phase 2 N=100 Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Misuse
Primary: Weekly Percentage of Heavy Drinking Days — 51.5; 52.9 percentage of days per week
Phase 2 N=377 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
Influenza, Human · COVID-19
Primary: SSA: Percentage of Participants With Local Reactions up to 7 Days Following Vaccination (18-64 Years) — 83.3; 89.3; 80.0; 63.3 Percentage of participants
Phase 2 N=25 Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Primary: Progression-Free Survival (PFS) — 8 years